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These data describe the phenotypic variability in a large cohort of
patients conﬁrmed to have homozygous familial hypercholester-
olemia. Herein, we describe the observed relationship of treated
low-density lipoprotein cholesterol with age. We also overlay the
low-density lipoprotein receptor gene (LDLR) functional status
with these phenotypic data. A full description of these data is
available in our recent study published in Atherosclerosis, “Pheno-
type Diversity Among Patients With Homozygous Familial
Hypercholesterolemia: A Cohort Study” (Raal et al., 2016) [1].
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
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 The stratiﬁcation of patients according to LDL receptor (LDLR) functionality adds further insight to
these data.
 Application of this type of assessment to other homozygous familial hypercholesterolemia (HoFH)
cohorts could add insight to phenotype and genotype variability.
 These data describe the relationship of age and treated low-density lipoprotein cholesterol (LDL-C).1. Data
Data are derived from 3 recent international studies comprising a total of 167 HoFH patients [1].
The relationship between patient age and treated LDL-C (tLDL-C) values is presented in the form of
scatter plot diagrams (Figs. 1 and 2).
Distribution curves of the LDL-C values for the 102 patients who had paired untreated LDL-C
(uLDL-C) and tLDL-C are shown in Fig. 3.
Table 1 lists the criteria endorsed by the European Atherosclerosis Society (EAS) Consensus Panel
on Familial Hypercholesterolemia [2].alues among patients in all cohorts with available tLDL-C data (n¼134). LDL-C indicates low-
; tLDL-C, treated low-density lipoprotein cholesterol.
Fig. 2. Patient age vs tLDL-C values among patients in all cohorts stratiﬁed by LDLR functional status. Def/Def indicates
defective/defective; LDLR, low-density lipoprotein receptor gene; Neg/Def, negative/defective; Neg/Neg, negative/negative;
tLDL-C, treated low-density lipoprotein cholesterol.
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The ﬁrst of the three datasets used for the present analysis consists of the baseline data pertaining
to patients enrolled in a phase 3, multicentre, international, randomised, double-blind, placebo-
controlled trial (the Genzyme [GZ] HoFH study, ClinicalTrials.gov number NCT00607373, sponsored
by Sanoﬁ Genzyme) comparing treatment with mipomersen vs placebo in patients with HoFH [3]. It
should be noted that the baseline LDL-C levels derived from this study reﬂect LDL-C levels prior to
treatment with mipomersen. The second dataset is derived from a published retrospective chart
review of patients treated at two specialised lipid clinics in South Africa (SA study) between 1972 and
2009 [4]. The third dataset is the published analysis of data derived from the national database of
patients with HoFH in the Netherlands, compiled by the Academic Medical Center in Amsterdam
(AMC study), a nationwide DNA diagnostic center where patients in the Netherlands are referred for
molecular diagnosis of familial hypercholesterolemia [5].
2.1. Diagnostic criteria
Diagnostic criteria for HoFH used in the GZ HoFH study and SA study were identical, and largely
mirror those of the EAS Consensus Panel: genetic conﬁrmation of two mutant alleles at the LDLR gene
locus or clinical diagnosis based on untreated LDL-C levels 413 mmol/L (500 mg/dL) in addition to
either xanthoma(s) observed before 10 years of age or evidence of heterozygous FH in both parents
[3,4]. Diagnostic criteria for the AMC study involved conﬁrmation of pathogenic mutations for
autosomal-dominant FH, speciﬁc to monogenic manifestations [5].
2.2. Exclusion criteria
Subjects meeting the following criteria were excluded: (1) subjects actively undergoing lipopro-
tein apheresis, (2) subjects with genetic conﬁrmation of a form of HoFH that did not directly involve
the LDLR gene (e.g., APOB), and (3) subjects who were deceased.
2.3. Phenotypic assessment
LDL-C levels were obtained at each center from medical records. Treated LDL-C (tLDL-C) refers to
the LDL-C level while the patient was taking the maximally tolerated available lipid-lowering
therapy (LLT).
Fig. 3. Distribution of LDL-C values by treatment status for patients in all cohorts with both uLDL-C and tLDL-C data (n¼102).
LDL-C indicates low-density lipoprotein cholesterol; tLDL-C, treated low-density lipoprotein cholesterol; uLDL-C, untreated
low-density lipoprotein cholesterol. Dotted line: distribution of patients with a particular tLDL-C; solid line: distribution of
patients with a particular uLDL-C.
Table 1
Clinical and genetic criteria for the diagnosis of homozygous familial hypercholesterolemia.
Clinical criteria Genetic criteria
Untreated LDL-C level 413 mmol/L
(500 mg/dL)
Genetic conﬁrmation of 2 mutant
alleles at the LDLR, APOB, PCSK9, or
LDLRAP1 gene locusOR
Treated LDL-C level Z8 mmol/L
(300 mg/dL)a
Accompanied by either:
a. Cutaneous or tendinous xanthoma
before age 10 years, or
b. Untreated, elevated LDL-C levels
consistent with HeFH in both
parents
The table is adapted with permission from Cuchel et al. [2].
HeFH, heterozygous familial hypercholesterolemia; HoFH, homozygous familial hypercholesterolemia; LDL-C, low-density
lipoprotein cholesterol; LDLR, low-density lipoprotein receptor gene; APOB, familial defective apolipoprotein B gene; PCSK9,
proprotein convertase subtilisin/kexin type 9 gene; LDLRAP1, LDL receptor adaptor protein 1 gene.
a LDL-C levels reﬂect a standard range; lower levels of LDL-C may be seen in HoFH, particularly in children and treated
patients.
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enrollment. Patient age in the AMC cohort was published online as supplemental data to the original
publication [5]. To be consistent with the GZ HoFH cohort, a conservative age was used for patients in
the SA lipid clinics, based on the year that enrollment began in the GZ HoFH study (i.e., 2007), instead
of using patient age at the time of this analysis.2.4. Molecular assessment
Molecular assessment was undertaken based on classiﬁcation of LDLR mutations into one of six
categories: (1) defective/defective, (2) defective/negative, (3) negative/negative, (4) defective/
unclassiﬁed, (5) negative/unclassiﬁed, or (6) unclassiﬁed/unclassiﬁed. An LDL receptor mutation
designated as “negative” is associated with o2% of LDL uptake in cultured ﬁbroblasts; a receptor
mutation designated as “defective” is associated with 2–25% of normal uptake [6]. If the receptor
F.J. Raal et al. / Data in Brief 7 (2016) 1458–14621462status was not reported or was unknown in the study publication, it was considered to be
unclassiﬁed.
2.5. Statistical analysis
The LDL-C distribution curves demonstrate the overlap of uLDL-C and tLDL-C values. For the
comparison of the AMC cohort and combined SA and GZ HoFH baseline cohorts, SAS software was
employed to perform a two-sample independent t-test. This comparison was chosen because patients
in the AMC study had a molecular diagnosis, whereas the SA and the GZ HoFH baseline cohorts had
predominantly a phenotypic diagnosis with conﬁrmation of HoFH using molecular diagnosis, if
available. Comparisons of the AMC study with the SAþGZ HoFH studies were conducted for both
uLDL-C and tLDL-C values. The relationship between patient age and tLDL-C values is presented in the
form of scatter plot diagrams (Figs. 1 and 2). Data regarding patient age at the time of the recording of
uLDL-C values were not always available.Acknowledgments
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